Englander Institute for Precision Medicine

Publications

Found 690 results
Author Title Type [ Year(Asc)]
2016
Meller S, Zipfel L, Gevensleben H, Dietrich J, Ellinger J, Majores M, Stein J, Sailer V, Jung M, Kristiansen G et al..  2016.  CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.. Epigenetics. 11(12):871-880.
Fontugne J, Davis K, Palanisamy N, Udager A, Mehra R, McDaniel AS, Siddiqui J, Rubin MA, Mosquera JMiguel, Tomlins SA.  2016.  Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.. Mod Pathol. 29(2):157-65.
Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JMiguel, Robinson B, Elemento O et al..  2016.  Clonal evolution of chemotherapy-resistant urothelial carcinoma.. Nat Genet. 48(12):1490-1499.
Goltz D, Holmes EEva, Gevensleben H, Sailer V, Dietrich J, Jung M, Röhler M, Meller S, Ellinger J, Kristiansen G et al..  2016.  CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.. Oncotarget. 7(33):53309-53320.
Rennert H, Eng K, Zhang T, Tan A, Xiang J, Romanel A, Kim R, Tam W, Liu Y-C, Bhinder B et al..  2016.  Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care.. NPJ Genom Med. 1:16019-.
Beltran H, Prandi D, Mosquera JMiguel, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BVSK, Varambally S et al..  2016.  Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.. Nat Med. 22(3):298-305.
Meller S, VAN Ellen A, Gevensleben H, Bicker A, Hankeln T, Gorr TA, Sailer V, Dröge F, Schröck F, Bootz F et al..  2016.  Ectopic Myoglobin Expression Is Associated with a Favourable Outcome in Head and Neck Squamous Cell Carcinoma Patients.. Anticancer Res. 36(12):6235-6241.
Pauli C, Puca L, Mosquera JMiguel, Robinson BD, Beltran H, Rubin MA, Rao RA.  2016.  An emerging role for cytopathology in precision oncology.. Cancer Cytopathol. 124(3):167-73.
Ribback S, Sailer V, Böhning E, Günther J, Merz J, Steinmüller F, Utpatel K, Cigliano A, Peters K, Pilo MG et al..  2016.  The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models.. Int J Mol Sci. 17(10)
Rubin MA, Girelli G, Demichelis F.  2016.  Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer.. Eur Urol. 69(4):557-560.
Ceder Y, Bjartell A, Culig Z, Rubin MA, Tomlins S, Visakorpi T.  2016.  The Molecular Evolution of Castration-resistant Prostate Cancer.. Eur Urol Focus. 2(5):506-513.
Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T et al..  2016.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.. Cancer Cell. 30(4):563-577.
Gevensleben H, Holmes EEva, Goltz D, Dietrich J, Sailer V, Ellinger J, Dietrich D, Kristiansen G.  2016.  PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.. Oncotarget. 7(48):79943-79955.
Sailer V, Holmes EEva, Gevensleben H, Goltz D, Dröge F, de Vos L, Franzen A, Schröck F, Bootz F, Kristiansen G et al..  2016.  PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma.. Oncotarget. 7(46):75827-75838.
Holmes EEva, Goltz D, Sailer V, Jung M, Meller S, Uhl B, Dietrich J, Röhler M, Ellinger J, Kristiansen G et al..  2016.   promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy.. Clin Epigenetics. 8:104.